What the FDA labels say about taking them together
Estrogens conjugated and medroxyprogesterone
Estrogens conjugated's FDA label of June 4, 2026 names medroxyprogesterone in its boxed warning section; the medroxyprogesterone labels PlainMeds reads (3) do not name estrogens conjugated. The estrogens conjugated label: “… during 5.6 years of treatment with daily oral CE (0.625 mg) combined with medroxyprogesterone acetate (MPA) [2.5 mg], relative to placebo.”
Check it at the source: the estrogens conjugated FDA label on DailyMed (effective June 4, 2026, Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc.); the medroxyprogesterone FDA label on DailyMed (effective June 29, 2026, Pharmacia & Upjohn Company LLC).
What does the estrogens conjugated label say about medroxyprogesterone?
Estrogens conjugated label, boxed warningThe WHI estrogen plus progestin substudy reported increased risks of DVT, pulmonary embolism (PE), stroke and myocardial infarction (MI) in postmenopausal women (50 to 79 years of age) during 5.6 years of treatment with daily oral CE (0.625 mg) combined with medroxyprogesterone acetate (MPA) [2.5 mg], relative to placebo [see Warnings and Precautions (5.1), and Clinical Studies (14.5) ].
Premarin label (Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc., May 30, 2025), boxed warningEstrogen Plus Progestin Therapy Cardiovascular Disorders and Probable Dementia Estrogen plus progestin therapy should not be used for the prevention of cardiovascular disease or dementia. (See CLINICAL STUDIES and WARNINGS, Cardiovascular disorders and Probable Dementia .) The WHI estrogen plus progestin substudy reported increased risks of DVT, pulmonary embolism (PE), stroke and myocardial infarction (MI) in postmenopausal women (50 to 79 years of age) during 5.6 years of treatment with daily oral CE (0.625 mg) combined with medroxyprogesterone acetate (MPA) [2.5 mg], relative to placebo. …
Source: FDA drug label (Premarin, NDA010402), Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc., effective May 30, 2025 (SPL set 87e2da8d-432c-4ed5-67a1-dc26294b2295), via openFDA
Source: FDA drug label (Premarin), Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc., effective June 4, 2026 (SPL set 258e1602-a3cf-4ccc-ca80-73dbbfb812ff), via openFDA; the full label on DailyMed
What does the medroxyprogesterone label say about estrogens conjugated?
Medroxyprogesterone's label (effective June 29, 2026) and its 2 other brand-application labels do not name estrogens conjugated in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Provera), NDA011839 (Pfizer), as published by Pharmacia & Upjohn Company LLC, effective June 29, 2026 (SPL set a586be28-96af-4fed-a13f-9b94fd4c7405), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Estrogens conjugated | Medroxyprogesterone | |
|---|---|---|
| Labeled for | Menopause symptoms, Breast cancer, Osteoporosis | Birth control, Pain |
| Boxed warning | Yes | Yes |
| Pharmacy cost (NADAC) | $5.47 per tablet 0.625 mg tablet | $22.85 per mL 150 mg/mL |
| Shortage now | No current entry | A presentation being discontinued |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once